|
Variable
|
Survivors (n = 663)
|
Non-survivors (n = 183)
|
P-value
|
|---|
|
Age (year)
|
62 ± 12
|
67 ± 12
|
< 0.001
|
|
Female n (%)
|
158 (24)
|
59 (32)
|
0.021
|
|
History of HF n (%)
|
11 (2)
|
15 (8)
|
< 0.001
|
|
Hypertension n (%)
|
301 (45)
|
107 (59)
|
0.002
|
|
Diabetes mellitus n (%)
|
117 (27)
|
77 (42)
|
< 0.001
|
|
Hyperlipidemia n (%)
|
94 (14)
|
31 (17)
|
0.351
|
|
Current smoking n (%)
|
210 (32)
|
41 (22)
|
0.015
|
|
Previous CAD n (%)
|
183 (28)
|
66 (26)
|
0.026
|
|
Prior stroke/TIA n (%)
|
21 (3)
|
19 (10)
|
< 0.001
|
|
Type of ACS n (%)
|
|
STEMI
|
419 (63)
|
105 (57)
|
0.151
|
|
NSTEMI
|
179 (27)
|
62 (34)
|
0.102
|
|
UA
|
56 (8)
|
13 (7)
|
0.557
|
|
Major bleeding n (%)
|
14 (2)
|
9 (5)
|
0.039
|
|
Killip class ≥2 n (%)
|
33 (5)
|
48 (26)
|
< 0.001
|
|
Medication at discharge
|
|
Beta-blocker n (%)
|
580 (88)
|
136 (74)
|
< 0.001
|
|
Statin n (%)
|
539 (81)
|
143 (78)
|
0.339
|
|
ACE-I/ARB n (%)
|
555 (84)
|
126 (99)
|
< 0.001
|
|
Outcomes
|
|
In-hospital death n (%)
|
0 (0)
|
30 (16)
|
< 0.001
|
|
Stroke n (%)
|
14 (2)
|
9 (5)
|
0.039
|
|
HF admission n (%)
|
24 (4)
|
25 (14)
|
< 0.001
|
|
Myocardial reinfarction n (%)
|
62 (9)
|
17 (9)
|
0.980
|
|
TVR n (%)
|
78 (12)
|
11 (6)
|
0.025
|
|
Cardiac death n (%)
|
0 (0)
|
59 (32)
|
< 0.001
|
- HF heart failure, CAD coronary artery disease, TIA transient ischemic attack, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, ACS acute coronary syndrome, UA unstable angina, NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation myocardial infarction, TVR target vessel revascularization
